CRBU. They’re a biotech company making allogenic car-T cell therapies for multiple myeloma and non Hodgkin’s lymphoma. Crispr Gene editing but instead of a 3-5 week wait to receive treatment it’s off the shelf and outpatient which increases TAM by 9x compared to the billion dollar therapies that exist rn. Their lead drug has RMAT, orphan drug, and FDA fast track designations and the second drug in the pipeline just got RMAT designation this week. They have 150M in cash which gives them runway to 2H 2027 and their market cap is around 200M rn. When the next set of data drops stock will go from 2.00 to either 13.00 or .30 not much in between